HemoGenix
Apr 08, 08
NEW STORY
16:39 ET
HemoGenix(R), Inc. Receives Issued Patent for its HALO(R) Technology Platform From the United States Patent and Trademark Office (USPTO).
Dec 05, 07
11:54 ET
HemoGenix(R) Introduces HALO(R)-96 PQR, the First Stem Cell Potency and Release Assay to Incorporate a Reference Standard.
Jun 22, 06
06:00 ET
HemoGenix(R) Launches HALO(TM) 384HT, the First Ever High Throughput Predictive Stem Cell Hemotoxicity Screening Platform
Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2008 PR Newswire Association LLC. ALL Rights Reserved.
A
United Business Media
company.